Loading...
OTCM
RGRX
Market cap86kUSD
Jun 30, Last price  
0.00USD
Name

RegeneRx Biopharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:RGRX chart
P/E
—
P/S
1.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.49%
Rev. gr., 5y
6.26%
Revenues
77k
0.00%
000272,491240,324168,4120849,5391,512,0001,342,84429,484060,61293,30856,65269,66776,76276,76176,76176,761
Net income
-2m
L+8.07%
-1,660,000-3,326,000-5,455,000-8,267,000-11,178,000-10,637,000-6,494,000-5,024,000-6,007,000-847,002-671,000-2,754,000-5,270,000229,125286,487-1,994,000-1,404,000-1,523,000-1,598,000-1,727,000
CFO
-941k
L-5.01%
-1,649,083-2,950,994-4,459,404-7,220,058-8,807,767-10,570,406-6,151,665-4,996,856-5,419,992-274,187-781,599-1,703,943-525,340-1,068,132-663,085-888,294-1,137,970-1,006,929-990,296-940,718

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

RegeneRx Biopharmaceuticals, Inc. is a biotechnology firm dedicated to the advancement of therapeutic peptides, with a primary emphasis on thymosin beta 4, engineered for the protection, repair, and regeneration of tissues and organs. The company's development pipeline includes RGN-259, a preservative-free ophthalmic solution designed to restore corneal tissues following injury, disease, or other pathologies; RGN-352, an injectable formulation under investigation for its potential in treating cardiovascular ailments, central and peripheral nervous system disorders, and various other medical conditions; and RGN-137, a topical gel aimed at accelerating the healing of skin wounds and minimizing scar tissue. Strategic alliances have been forged with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. Incorporated in 1982, the company initially operated as Alpha 1 Biomedicals, Inc., adopting the name RegeneRx Biopharmaceuticals, Inc. in 2000. Its operations are headquartered in Rockville, Maryland.
URL
http://www.regenerx.com/
IPO date
Dec 23, 1986
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT